Clinical Trial Update: Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating brexpiprazole for long-term treatment of agitation in Alzheimer's-type dementia has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19